Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
Капзатраты
A1 A2 A3 A4 A5
REGN
FY2026 Q1
Улучшается
Отчётный звонок Regeneron Pharmaceuticals, Inc.
Вывод Buzzberg
Dupixent growth and margin improvement expected to boost collaboration revenue
Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47.
Вывод Buzzberg Dupixent growth and margin improvement expected to boost collaboration revenue Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47. Читать полный анализСвернуть анализ
Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47.
- Dupixent global sales grew 31% to $4.9B, with new indications approved.
- ILEA franchise is bifurcating: ILEA-HD +52% YoY, ILEA declining as biosimilars approach.
- Pipeline progress highlighted: positive Phase 3 for C5 siRNA in MG, Phase 3 data for GLP-1/GIP partner, and BLA acceptance for garitosumab.
Выручка$3.6054B-7% к/к
EPS$9.47-17% к/к
Валовая маржа81.43%Факт
Операционная маржа17.83%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Pipeline
Fianelmab melanoma PFS data expected later this quarter
Regulatory
Eylea HD PFS decision expected this quarter after FDA miss
Показать ещё 3 тезиса
Capital Allocation
New $3 billion buyback authorized, with $3.4 billion available
Pipeline
Obesity combo with Praluent positioned as preferred GLP-1
Data
Linazific infectious risk decreases with longer treatment
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $3.6054B | -7% к/к |
| EPS | $9.47 | -17% к/к |
| Валовая маржа | 81.43% | Факт |
| Операционная маржа | 17.83% | Факт |
| Свободный денежный поток | $0.8483B | -8% к/к |
| Капзатраты | $0.2306B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Валовая маржа | FY2026 | 77%–78% | 77.5% | Подтверждён |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management struck a confident tone, highlighting strong commercial execution, pipeline progress, and a new share repurchase authorization, while framing challenges like the FDA delay on the pre-filled syringe as near-term issues.
Инвестиции и мощности
Management noted a temporary interruption in bulk manufacturing at its Limerick, Ireland site, which has resumed initial production and is expected to return to full production by the end of the second quarter. GAAP gross margin guidance was lowered to 77%-78% due to related costs, but product availability was not impacted.
все упомянутые компании ниже: 1
Компаниис момента звонка
Партнёры
Партнёры
Dr. Leonard Schleifer
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue. — This is a significant, durable revenue tailwind for Regeneron from Q3 onwards.
Доказательства
“Maybe it'll give me an opportunity to publicly thank Paul Hudson for all the work he did on Dupixent since 2019...”
Внешние сигналы
Альфа цепочки поставок · 5с момента звонка
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue.
Доказательства
“We now expect the Sanofi development balance to be fully repaid by the end of the second quarter. As a result, we expect Sanofi collaboration revenue to step up to reflect our full share of collaboration profits starting in the third quart…”
ILEA (Eylea) demand is expected to decline in the mid-to-high teens QoQ in Q2 ahead of new biosimilar launches, while ILEA-HD demand grows ~10% sequentially.
Доказательства
“...for ILEA, we anticipate that demand will decline in the mid to high teens in the second quarter ahead of the potential launch of additional biosimilars in the second half of the year coupled with the factors that I highlighted earlier.”
Regeneron has a strategic goal to match up to $200 million in 2026 for patient assistance contributions via Good Days, with Q1 contributions de minimis.
Доказательства
“We remain committed to matching up to $200 million in 2026 to support patient access and affordability.”
GAAP gross margin will be negatively impacted in Q2 due to a temporary interruption in bulk manufacturing at Limerick, Ireland, with production resuming to full capacity by end of Q2.
Доказательства
“We have now resumed initial production in the facility and expect to resume full production by the end of the second quarter. As a result, we anticipate our GAAP gross margin will continue to be negatively impacted in the second quarter as…”
Regeneron is developing next-gen IL-13 antibodies and is planning an expedited path to approval, seeking to broaden the atopic dermatitis market to include mild patients.
Доказательства
“We don't necessarily think about having to exactly replace or work on. We have nearly 50 things in the pipeline, and we're looking forward to bringing as many important ones forward as we can.”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 1. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.